<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00312325</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-030602</org_study_id>
    <nct_id>NCT00312325</nct_id>
  </id_info>
  <brief_title>Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans</brief_title>
  <official_title>Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      Because of their antiinflamatory effects, glucocorticoids are often used to reduce edema in&#xD;
      neurologic tissue and to otherwise mitigate the consequences of neural inflammation. For&#xD;
      example, high dose prednisolone treatment has been shown to be an effective therapy for&#xD;
      different eye diseases including severe Graves´ Ophthalmopathy and acute optic neuritis.&#xD;
      However, contradictory results exists for the influence of high dose prednisolone therapy per&#xD;
      se on tissue blood flow. Thus, in the current study, we plan to investigate the effect of&#xD;
      high dose, short time therapy with intravenous prednisolone in patients with optic neuritis&#xD;
      and severe Graves´ Ophthalmopathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date>August 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non invasive measurement of optic nerve and choroidal blood flow</measure>
  </primary_outcome>
  <enrollment>24</enrollment>
  <condition>Regional Blood Flow</condition>
  <condition>Optic Disk</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged between 19 and 65 years, nonsmokers&#xD;
&#xD;
          -  Group A: Patients with Graves´ Ophthalmopathy (moderate to severe and active&#xD;
             ophthalmopathy; i.e. clinical activity score &gt;3 or =3) suitable for high-dose&#xD;
             treatment with prednisolone as assessed by an independent ophthalmologist&#xD;
&#xD;
          -  Group B: Patients with acute onset of optic neuritis suitable for high-dose treatment&#xD;
             with prednisolone suitable for high-dose treatment with prednisolone as assessed by&#xD;
             the ophthalmologist&#xD;
&#xD;
          -  Normal laboratory values unless the investigator considers an abnormality to be&#xD;
             clinically irrelevant and not to interfere with prednisolone treatment (normal liver&#xD;
             blood parameter and hepatitis serology).&#xD;
&#xD;
          -  Ametropy of less than 3 dpt.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Regular use of medication which could interfere with the study objectives, especially&#xD;
             treatment with vasoactive drugs&#xD;
&#xD;
          -  Active peptic ulcer or insulin dependent diabetes mellitus&#xD;
&#xD;
          -  Hepatitis or elevated hepatic blood parameters&#xD;
&#xD;
          -  Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks&#xD;
             preceding the study&#xD;
&#xD;
          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day&#xD;
&#xD;
          -  Blood donation during the previous 3 weeks&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriele Fuchsjaeger-Mayrl, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2006</verification_date>
  <study_first_submitted>April 6, 2006</study_first_submitted>
  <study_first_submitted_qc>April 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2006</study_first_posted>
  <last_update_submitted>April 7, 2006</last_update_submitted>
  <last_update_submitted_qc>April 7, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2006</last_update_posted>
  <keyword>Optic nerve head blood flow</keyword>
  <keyword>Choroidal blood flow</keyword>
  <keyword>Prednisolone</keyword>
  <keyword>Graves´ Ophthalmopathy</keyword>
  <keyword>optic neuritis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

